Role of adam10 and its relevance to disease and therapeutics
AssigneeThe University of Chicago
InventorJuliane Bubeck Wardenburg
Life of this patent
Estimating the term…
Abstract
Certain embodiments are directed to compositions and methods of inhibiting pathogenic bacterial infection involving ADAMIO comprising administering an effective amount of a metalloprotease inhibitor to a patient. Certain embodiments are directed to method of inhibiting Staphylococcal infection comprising administering an effective amount of a metalloprotease inhibitor to a patient. Other embodiments concern methods of inhibiting infection by a bacteria from the genus Clostridium, Streptococcus, Listeria, Bacillus, or Arcanobacterium.
Claims31
A method of inhibiting Staphylococcal infection comprising administering an effective amount of a metalloprotease inhibitor to a patient, wherein the patient has been determined to have or be at risk of developing a Staphylococcal infection, wherein the metalloprotease inhibitor is an inhibitor of A Disintegrin and Metalloprotease 10 (ADAM10).
(canceled)
(canceled)
(canceled)
10-23. (canceled)
26-36. (canceled)
A method of ameliorating disruption of an epithelial membrane comprising contacting an epithelial membrane that has been exposed to a pore-forming toxin with an inhibitor of A Disintegrin and Metalloprotease 10 (ADAM10).
40-97. (canceled)
A method for preventing disruption of a subject's epithelial barrier comprising administering an effective amount of a metalloprotease inhibitor to the subject, wherein the subject has been determined to have or be at risk for a Staphylococcal infection, wherein the metalloprotease inhibitor is an inhibitor of A Disintegrin and Metalloproteinase 10 (ADAM10).
(canceled)
101-102. (canceled)
107-115. (canceled)
117-120. (canceled)
122-126. (canceled)
Dependencies are inferred from the claim text.